Information Library

Results for: Product Development & Commercialization - Partnership Structures

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • PHARMAXIS SELECTS QUINTILES TO COMMERCIALIZE BRONCHITOL

    Press Release — August 31, 2010 – Quintiles announced a strategic agreement with Pharmaxis to provide a broad range of commercial solutions to support the European launch of Bronchitol®, an innovative treatment for cystic fibrosis.

  • Targeting Oncology

    Brochure — June 2, 2010
    Learn more about Quintiles leadership in oncology product development and commercialization.

  • Focused Co-Promotion

    Case Study — May 9, 2010
    Roche Italy needed to find new, cost-effective ways to underpin sales of mature products. Uncover what happened when a unique partnership with Quintiles reinforced sales growth.

  • PharmAsia News Article Reprint

    Media Coverage — March 1, 2010
    Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News.

  • QUINTILES OPENS EXPANDED ASIA-PACIFIC HEADQUARTERS IN SINGAPORE

    Press Release — November 6, 2009 - To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles announced the official grand opening of its expanded Asia-Pacific regional headquarters facility in Singapore's Science Park I.

  • QUINTILES ANNOUNCES CLINICAL RESEARCH PARNERSHIP WITH THE UNIVERSITY OF PRETORIA

    Press Release — September 10, 2009 – Quintiles Prime Site Program expands into South Africa to accelerate clinical development.

  • Anatomy of a Managed Partnership

    Hear from the Experts — May 26, 2009
    Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs.

  • Gain Capital & Retain Value

    Case Study — March 24, 2009
    Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product.

  • Jumpstarting a Phase III Candidate

    Case Study — March 24, 2009
    A global pharmaceutical company had a promising new formulation of a marketed product in early Phase III trials, but R&D budget pressures were likely to result in delays getting the product to market.

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences